

Novel Sydnone Derivatives Carrying Azidomethyl-1,2,4-oxadiazole Unit and their 1,3-dipolar Cycloadditions

Yaşar Dürüst¹, Elif Yıldız¹, Hamza Karakuş¹, Benson M. Kariuki²

¹Department of Chemistry, Abant İzzet Baysal University, Turkey


²School of Chemistry, Cardiff University, Cardiff, UK

Corresponding author Yaşar Dürüst . Email: yasardurust@ibu.edu.tr

Abstract

A series of 1,2,4-oxadiazolymethyl sydnones carrying azido group were synthesized and subjected to react with a variety of alkenic and acetylenic dipolarophilic reagents; *N*-phenyl maleimide, phenyl vinyl sulfone and phenyl propiolic acid. All the new products are identified by means of spectral/physical data including high resolution mass measurements and X-ray diffraction data.

Graphical Abstract



KEYWORDS: sydnone; oxadiazole; triazole; azide; 1,3-dipolar cycloaddition

INTRODUCTION

Sydrones are among the important class of mesoionic systems which were discovered by Earl and Mackney^[1] and they have been receiving an increasing interest over the decades due to their capability to be converted into heterocycles with potent biological activities.^[2-4] The electrophilic substitution of sydrones in C4 position is a well known method for the preparation of a wide range of 4-heterocycle-substituted sydrones.^[5,6]

1,2,4-Oxadiazole derivatives are also important skeletons of biologically or pharmacologically important compounds. For example, muscarinic agonists, histamine H3 antagonists, antitumoral, antiinflammatory and antimycobacterium tuberculosis agents containing a 1,2,4-oxadiazole ring are among them.^[7-12] On the other hand, triazole rings have also attracted remarkable attention due to their biological activities such as antifungal, anticonvulsant agents and especially popular in designing anticancer agents.^[13-17]

1,3-Dipolar cycloaddition route is a valuable process in order to assemble molecules having fragments in biologically active agents of 5-membered nitrogen heterocycles. From a synthetic standpoint, it may be considered worthy and in principle, available by a sequence involving sydrone functionalization with azido group followed by cycloaddition.

Taking account of above considerations together with our continuing interest in the 1,3-dipolar cycloaddition chemistry of various ylides leading to triazoles and spiropyrroles,^[18-21] we focus herein on the synthesis of oxadiazolyl-substituted sydrones

starting from sydnones and their carboxamidoxime derivatives which were subsequently converted into azidomethyl compounds. The latter were engaged in a series of representative electron-deficient alkenes and alkynes: and their cycloaddition reactions. These series of sydnones were reacted with three representative dipolarophiles: *N*-phenyl maleimide, phenyl vinyl sulfone, and phenyl propiolic acid.

RESULTS AND DISCUSSION

N-Aryl sydnones **5a-f** have been synthesized starting from 4-substituted anilines **1** through cyclodehydration of corresponding *N*-nitroso α -amino carboxylic acids **4** according to the previously reported procedures (Scheme 1).^[22,23] In this way, we have prepared 6 sydnone derivatives.

In order to convert sydnones **5** into 4-carboxamidoxime derivatives **9**, a reaction sequence has been utilized, which, first, transformed starting materials to sydnone aldehydes **6** by means of Vilsmeier-Haack formylation.^[24] Aldehydes **6** were then transformed into aldoximes **7** which were dehydrated to give nitriles **8**.^[25] Sydnone nitriles **8** have been reacted with hydroxylamine to yield sydnone amidoximes **9** (Scheme 2). In this way, we have prepared 3 sydnone carboxamide oximes.

Sydnone-4-carboxamidoximes **9** have been converted into 5-chloromethyl-3-substitutedphenyl-1,2,4-oxadiazoles **10a-c**^[26] by their reaction with chloroacetyl chloride in benzene under reflux. Sydnone azides **11a-d** were obtained from the reaction of oxadiazoles **10a-d** with NaN_3 according to previously reported procedure (Scheme 3).^[21]

Among the important spectral characteristics of these novel compounds are azide and carbonyl stretching absorptions in the IR spectra at around 2100 and 1750 cm^{-1} ; CH_2 protons and carbon at around 4.50 and 45 ppm, respectively, in the NMR spectra.

One of the chloromethyl oxadiazolyl sydnone, **10c** has been elucidated by obtaining X-Ray ORTEP view (Figure 1).

Sydnone azides **11a-c** were then subjected to 1,3-dipolar cycloaddition with *N*-phenyl maleimide **12** to give cycloadducts **13a-c** which were absolutely identified by means of X-ray diffraction data (Scheme 4, Figure 2).

Upon examination of the IR data, strong absorptions arising from both sydnone and maleimide portions of the cycloadducts at around 1770 -1720 cm^{-1} were observed. ^1H NMR spectra also showed the methylene protons as separate doublets at around 5.55 and 5.20 ppm while the bridge protons resonated as doublets at 5.65 and 4.55 ppm. Carbonyl carbons appeared at 175-165 ppm region, bridge carbons at around 83 and 56 ppm and methylene carbons at 44 ppm, respectively. These results are in accord with the previous findings.^[21] We were also able to obtain an X-ray ORTEP diagram of **13b** (Figure 2).

Azido sydnone **11a** and **11b** were also assayed for 1,3-dipolar cycloaddition with electron deficient alkene, phenyl vinyl sulfone **14** and cycloadducts **15a,b** were obtained in lower yields 13% and 10% respectively (Scheme 5).

Spectral characteristics of these cycloadducts included a carbonyl absorption in the IR spectrum emerged from the sydnone fragment, symmetric and asymmetric stretching vibrations of sulfone moiety at 1325-1140 cm^{-1} . The proton NMR signals of the triazoline ring and methylene hydrogens existing in the region of 5.60-3.50 ppm were indicative. All these resonances coincide with the previous reports regarding the associated compounds.^[27,28] We have utilized a number of different reaction conditions for other azido sydnones (**11c,d**) to obtain a variety of cycloadducts carrying phenyl sulfonyl group, but all the attempts failed, that is, no triazole products could form.

In order to explore the cycloaddition of novel azides with an alkyne dipolarophile; we used phenyl propiolic acid **16** and it smoothly underwent cycloaddition to afford the cycloadducts **17a-d** with the azido sydnones **11a-d** (Scheme 6).

1,3-Dipolar cycloaddition of azido sydnones **11a-d** with phenyl propiolic acid resulted in regioselective formation of the 4-phenyl regioisomers (triazoline ring numbering) but not 5-phenyl regioisomers which is supported by the X-ray diffraction data of **17b** (Figure 3), as well as by an earlier report utilizing electron-deficient alkyne esters.^[25] Indicative spectral characteristics are the carbonyl absorptions of sydnone part, and C=N absorptions in the IR spectra. ^1H NMR spectra of products showed a triazole proton at around 7.90 ppm and methylene protons at around 5.90 ppm.

We also attempted to carry out a second cycloaddition with the sydnone fragment of the cycloadducts but despite numerous trials no reaction occurred; much likely to be

attributed to the sterical bulkiness around the ylide that prevents from the approach of dipolarophiles.

One of our goals associated with this work, was to screen the novel products for their bioactivities, but, due to low amounts of the end products, it was not possible at this moment. However, we have made some predictions by means of Lipinski's rule of five (RO5), a rule of thumb to evaluate druglikeness or determine if a chemical compound with a certain pharmacological or biological activity has properties that would make it a likely orally active drug in humans.^[29-31] Below is given a table indicating the estimated Lipinski values (Table 1). In this regard, higher scores are related to the methoxy and methyl substituted adducts.

CONCLUSION

Through this work we have demonstrated a ten-step reaction sequence leading to the synthesis of the novel sydnones bearing azidomethyl-1,2,4-oxadiazole fragment and their 1,3-dipolar cycloaddition reaction with a series of electron deficient dipolarophilic reagents; *N*-phenyl maleimide, phenyl vinyl sulfone and phenyl propiolic acid. The compounds **13**, **15** and **17** resulted from 1,3-dipolar cycloaddition of the sydnone azides preferentially by azide-dipolarophile reaction, but no further reactivity has been observed between sydnone-azide cycloadducts and dipolarophiles even if too many reaction conditions were assayed.

EXPERIMENTAL

Melting points were determined on a Meltemp apparatus and are uncorrected. Infrared spectra were obtained from KBr pellets or neat on NaCl plates for liquids and were recorded on a SHIMADZU FTIR-8400S spectrophotometer. NMR spectra were recorded on Jeol and Varian spectrometers operating at 400 MHz for ^1H and at 100 MHz for ^{13}C , all at 25 °C, as specified for each data set. LC-MS spectra were obtained from Waters 2695 Alliance Micromass ZQ instrument. High Resolution Mass Spectra have been obtained from Waters Lct Premier XE oa-TOF Mass Spectrometer (Waters Corporation, Milferd, MA, USA). Single crystal X-ray diffraction data were obtained by Bruker Smart Apex II Quazar and Nonius Kappa CCD instruments. All chemical shifts are reported in ppm relative to TMS. Coupling constants (J) are reported in Hz. Routine TLC analyses were carried out on pre-coated silica gel plates with fluorescent indicator. Flash column chromatography was performed on silica gel (230-400 Mesh ASTM). A rotary TLC apparatus (Chromatotron) was utilized for further separation and purifications. Stain solutions of potassium permanganate and iodine were used for visualization of the TLC spots.

Typical Reaction Procedure For The Synthesis Of 4-(5-(Chloromethyl)-1,2,4-

Oxadiazol-3-Yl)-3-(4-Methylphenyl)Sydnone (10a)^[22]

A solution of chloroacetylchloride (0.070 g, 0.62 mmol) in benzene (2 mL) was added dropwise to a solution of 3-(4-methoxyphenyl)sydnone-4-carboxamidoxime **9a** (0.360 g, 1.54 mmol) in benzene (20 mL) and the mixture was heated under reflux for 24h. The progress of the reaction was monitored by TLC. The reaction mixture was concentrated

in vacuo, and the crude residue was purified by flash column chromatography (*n*-hexane:ethyl acetate; 4:1) to give **10a** as a white solid.

4-(5-(Chloromethyl)-1,2,4-Oxadiazol-3-Yl)-3-(4-Methylphenyl)Sydnone (10a)

Yield: 0.400 g, 89%. Mp. 155-156°C. R_f: 0.59 (*n*-hexane:ethyl acetate; 1:1). IR (KBr, ν :cm⁻¹): 3014, 2960, 1797, 1778 (sydnone C=O), 1568 (C=N), 1510, 1444, 1282, 1199, 1058, 1010, 954, 891, 779, 750 (C-Cl). ¹H NMR (400 MHz, CDCl₃): δ_{H} = 7.45 (d, *J*=8.4 Hz, 2H), 7.41 (d, *J*=8.4 Hz, 2H), 4.66 (s, 2H), 2.51 (s, 3H). ¹³C NMR (100 MHz, CDCl₃): δ_{C} = 174.5 (sydnone C=O), 158.5 (C=N), 143.6, 130.3, 124.7, 32.9 (CH₂), 21.6 (CH₃). LC-MS (80 eV) (*m/z*) (%): 356 ([M+CH₃CN+Na]⁺, 100), 293 ([M+H]⁺, 48), 248 (21). HRMS: *m/z* (ESI-TOF, [M+H]⁺) calcd for C₁₂H₁₀N₄O₃Cl: 293.0441; found: 293.0428.

Typical Reaction Procedure For The Synthesis Of 4-(5-(Azidomethyl)-1,2,4-Oxadiazol-3-Yl)-3-(4-Methylphenyl)Sydnone (11a)^[19,23]

To a stirred solution of 4-(5-(chloromethyl)-1,2,4-oxadiazol-3-yl)-3-(4-methylphenyl)sydnone **10a** (0.400 g, 1.37 mmol) in a 10 mL water/acetone mixture (1:4) was added sodium azide (0.098 g, 1.51 mmol). The resulting suspension was stirred at room temperature for 24h. Dichloromethane (DCM) was added to the mixture and the organic layer was separated. The aqueous layer was extracted with 3x10 mL aliquots of DCM and the combined organic layers were dried over sodium sulfate. Solvent was removed under reduced pressure to give **11a** as a light yellow solid.

4-(5-(Azidomethyl)-1,2,4-Oxadiazol-3-Yl)-3-(4-Methylphenyl)Sydnone (11a)

Yield: 0.200 g, 49%. Mp. 98-101°C. R_f: 0.58 (*n*-hexane:ethyl acetate; 1:1). IR (KBr, v:cm⁻¹): 3061, 2991, 2922, 2098 (N=N=N), 1759, 1743 (C=O), 1558 (C=N), 1508, 1435, 1319, 1273, 1197, 1056, 1016, 960, 817, 740. ¹H NMR (400 MHz, CDCl₃): δ_H= 7.44 (d, *J*=8.8 Hz, 2H), 7.40 (d, *J*=8.8 Hz, 2H), 4.51 (s, 2H), 2.49 (s, 3H). ¹³C NMR (100 MHz, CDCl₃): δ_C= 174.2 (sydnone C=O), 164.8 (C=N), 158.4 (C=N), 143.4, 131.8, 130.3, 124.5, 44.6 (CH₂), 21.5 (CH₃). LC-MS (80 eV) (*m/z*) (%): 363 ([M+CH₃CN+Na]⁺, 94), 300 ([M+H]⁺, 100). HRMS: *m/z* (ESI-TOF, [M+H]⁺) calcd for C₁₂H₁₀N₇O₃: 300.0845; found: 300.0834.

Typical Reaction Procedure For The Synthesis Of 4-(5-(((3*as*,6*ar*)-4,6-Dioxo-5-Phenyl-4,5,6,6*a*-Tetrahydropyrrolo[3,4-*D*][1,2,3]Triazol-1(3*ah*)-Yl)Methyl)-1,2,4-Oxadiazol-3-Yl)-3-(4-Methylphenyl)Sydnone (13*a*)

A mixture of *N*-phenyl maleimide **12** (0.030 g, 0.175 mmol) and 4-(5-(azidomethyl)-1,2,4-oxadiazol-3-yl)-3-(4-methylphenyl)sydnone **11a** (0.050 g, 0.167 mmol) were stirred in benzene (17 mL) and the mixture was heated under reflux for 2-4 d. The reaction was monitored by TLC. The reaction mixture was concentrated *in vacuo*, and the crude residue was purified by flash column chromatography (*n*-hexane:ethyl acetate; 1:2) to give **13a** as a light yellow solid.

4-(5-(((3*as*,6*ar*)-4,6-Dioxo-5-Phenyl-4,5,6,6*a*-Tetrahydropyrrolo[3,4-*D*][1,2,3]Triazol-1(3*ah*)-Yl)Methyl)-1,2,4-Oxadiazol-3-Yl)-3-(4-Methylphenyl)Sydnone (13*a*)

Yield: 0.020 g, 25%. Mp. 143-144°C. R_f: 0.19 (*n*-hexane:ethyl acetate; 1:1). IR (KBr, v:cm⁻¹): 1766 (sydnone C=O), 1720 (C=O), 1564 (C=N), 1492, 1379, 1195, 1041, 817,

742. ^1H NMR (400 MHz, CDCl_3): $\delta_{\text{H}} = 7.48\text{--}7.38$ (m, 4H), 7.35 (d, $J = 2.8$ Hz, 2H), 7.2 (t, $J = 2.0$ Hz, 1H), 7.19 (t, $J = 1.6$ Hz, 1H), 5.62 (d, $J = 10.8$ Hz, 1H), 5.48 (d, $J = 18.0$ Hz, 1H), 5.22 (d, $J = 18.0$ Hz, 1H), 4.56 (d, $J = 10.8$ Hz, 1H), 2.51 (s, 3H). ^{13}C NMR (100 MHz, CDCl_3): $\delta_{\text{C}} = 174.3$ (sydnone C=O), 170.9 (C=O), 168.3 (C=O), 164.8 (C=N), 158.1 (C=N), 143.7 (C- CH_3), 131.7, 130.4, 129.5, 129.3, 126.8, 126.3, 126.0, 124.6, 83.2 (CH), 57.0 (CH), 44.3 (CH_2), 21.5 (CH_3). HRMS: m/z (ESI-TOF, $[\text{M}+\text{H}]^+$) calcd for $\text{C}_{22}\text{H}_{17}\text{N}_8\text{O}_5$: 473.1322; found: 473.1325.

Typical Reaction Procedure For The Synthesis Of 3-(4-Methylphenyl)-4-(5-((5-(Phenylsulfonyl)-4,5-Dihydro-1H-1,2,3-Triazol-1-Yl)Methyl)-1,2,4-Oxadiazol-3-Yl)Sydnone (15a)

A mixture of phenyl vinyl sulfone **14** (0.024 g, 0.135 mmol) and 4-(5-(azidomethyl)-1,2,4-oxadiazol-3-yl)-3-(4-methylphenyl)sydnone **11a** (0.040 g, 0.134 mmol) were stirred in toluene (7 mL) and the mixture was heated under reflux for 6d. The reaction was monitored by TLC. The reaction mixture was concentrated *in vacuo*, and the crude residue was purified by flash column chromatography (*n*-hexane:ethyl acetate; 1:2) to give **15a** as a light yellow solid.

3-(4-Methylphenyl)-4-(5-((5-(Phenylsulfonyl)-4,5-Dihydro-1H-1,2,3-Triazol-1-Yl)Methyl)-1,2,4-Oxadiazol-3-Yl)Sydnone (15a)

Yield: 8mg, 13%. Mp. 84-86°C. R_f : 0.20 (*n*-hexane:ethyl acetate; 1:1). IR (KBr, $\text{v}:\text{cm}^{-1}$): 2958, 2927, 2852, 1770 (sydnone C=O), 1564 (C=N), 1446, 1321 (asym SO_2), 1240, 1151 (sym SO_2), 1082, 1056, 935, 821, 744. ^1H NMR (400 MHz, CDCl_3): $\delta_{\text{H}} = 7.95$ (dd,

$J=8.0, 0.4$ Hz, 2H), 7.72 (t, $J=7.6$ Hz, 1H), 7.60 (t, $J=8.0$ Hz, 2H), 7.42 (dd, $J=11.6, 8.8$ Hz, 4H), 5.56 (dd, $J=8.4, 7.2$ Hz, 1H), 5.19 (d, $J=17.6$ Hz, 1H), 4.96 (d, $J=17.2$ Hz, 1H), 3.85 (dd, $J=11.6, 7.6$ Hz, 1H), 3.52 (t, $J=12.0$ Hz, 1H), 2.47 (s, 3H). ^{13}C NMR (100 MHz, CDCl_3): $\delta_{\text{C}}= 173.5$ (sydnone C=O), 164.7 (C=N), 158.2 (C=N), 143.6 (C-CH₃), 136.0, 134.8, 131.7, 130.3, 129.5, 129.3, 124.7, 95.1 (C-SO₂), 44.9 (CH₂), 44.2 (CH₂), 21.5 (CH₃). LC-MS (80 eV) (m/z) (%): 490 ($[\text{M}+\text{Na}]^+$, 100), 468 ($[\text{M}+\text{H}]^+$, 19), 459 (60). ESI-MS (80 eV) (m/z) (%): 466 ($[\text{M}-\text{H}]$, 100). HRMS: m/z (ESI-TOF, $[\text{M}+\text{H}]^+$) calcd for $\text{C}_{20}\text{H}_{18}\text{N}_7\text{O}_5\text{S}$: 468.1090; found: 468.1081.

Typical Reaction Procedure For The Synthesis Of 3-(4-Methylphenyl)-4-(5-((5-Phenyl-1H-1,2,3-Triazol-1-Yl)methyl)-1,2,4-Oxadiazol-3-Yl)Sydnone (17a)

Method A

A mixture of phenylpropionic acid **16** (0.026 g, 0.175 mmol) and 4-(5-(azidomethyl)-1,2,4-oxadiazol-3-yl)-3-(4-methylphenyl)sydnone **11a** (0.050 g, 0.167 mmol) were stirred in benzene (17 mL) and the mixture was heated under reflux for 4d. The reaction was monitored by TLC. But, no reaction occurred.

Method B

A mixture of 4-(5-(azidomethyl)-1,2,4-oxadiazol-3-yl)-3-(4-methylphenyl)sydnone **11a** (0.050 g, 0.167 mmol), catalytic amount of $\text{CuSO}_4 \cdot 5\text{H}_2\text{O}$ (0.002 g, 0.008 mmol), Na-L-ascorbate (0.009 g, 0.043 mmol) and phenylpropionic acid **16** (0.026 g, 0.175 mmol) were stirred in *t*-BuOH/water mixture (1 mL;2 mL, 1:2) at room temperature for 2d. Then, the

reaction mixture was extracted with ethyl acetate three times. The combined organic layers were dried over sodium sulfate. The solvent was evaporated under reduced pressure to give **17a** as a brown solid.

3-(4-Methylphenyl)-4-(5-((5-Phenyl-1H-1,2,3-Triazol-1-yl)methyl)-1,2,4-Oxadiazol-3-yl)sydnone (17a)

Yield: 0.060 g, 90%. Mp. 129-131°C. R_f: 0.21 (*n*-hexane:ethyl acetate; 1:1). IR (KBr, ν :cm⁻¹): 3047, 2935, 1780 (sydnone C=O), 1625, 1568 (C=N), 1450, 1338, 1232, 1068, 908, 815, 761. ¹H NMR (400 MHz, CDCl₃): δ_{H} = 7.88 (s, 1H), 7.80 (d, *J*=7.2 Hz, 2H), 7.44 (t, *J*=7.2 Hz, 2H), 7.40-7.34 (m, 3H), 7.29 (d, *J*=8.4 Hz, 2H), 5.85 (s, 2H), 2.34 (s, 3H). ¹³C NMR (100 MHz, CDCl₃): δ_{C} = 167.4 (sydnone C=O), 164.8 (C=N), 143.7, 131.5, 130.2, 129.7, 128.9, 128.6, 125.7, 124.6, 124.1, 120.2, 96.8, 45.0 (CH₂), 21.4 (CH₃). LC-MS (80 eV) (*m/z*) (%): 424 ([M+Na]⁺, 83), 402 ([M+H]⁺, 100), 282 (93). ESI-MS (80 eV) (*m/z*) (%): 400 ([M-H]⁻, 100). HRMS: *m/z* (ESI-TOF, [M+H]⁺) calcd for C₂₀H₁₆N₇O₃: 402.1315; found: 402.1296.

SUPPORTING INFORMATION

Full experimental detail, ¹H and ¹³C NMR spectra for synthesized compounds and X-ray data for compounds **10c** (CCDC No:1005653), **13b** (CCDC No: 1024963) and **17b** (CCDC No: 1019441). This material can be found via the “Supplementary Content” section of this article’s webpage.

ACKNOWLEDGMENTS

Abant İzzet Baysal University, Directorate of Research Projects Commission (BAP grant no. 2012.03.03.557) is gratefully acknowledged for financial support. Authors thank Dr. Yunus Zorlu (Gebze Technical University, Kocaeli, Turkey) for X-ray diffraction data.

REFERENCES

- [1] Earl, J. C.; Mackney, A. W. *J. Chem. Soc.* **1935**, 899-900.
- [2] Browne, D. L.; Harrity, J. P. A. *Tetrahedron* **2010**, 66, 553–568.
- [3] Specklin, S.; Decuypere, E.; Plougastel, L.; Aliani, S.; Taran, F. *J. Org. Chem.* **2014**, 79, 7772-7777.
- [4] Delaunay, T.; Genix, P.; Es-Sayed, M.; Vors, J. P.; Monteiro, N.; Balme, G. *Org. Lett.* **2010**, 12, 3328-3331.
- [5] Bohle, D. S.; Perepichka, I. *J. Org. Chem.* **2009**, 74, 1621-1626.
- [6] Takagi, K.; Shiro, M.; Takeda, S.; Nakamura, N. *J. Am. Chem. Soc.* **1992**, 114, 8414-8416.
- [7] Foster, R. S.; Adams, H.; Jakobi, H.; Harrity, J. P. A. *J. Org. Chem.* **2013**, 78, 4049-4064.
- [8] Takayuki, N.; Susumu, N.; Kiyoshi, T.; Kenji, M.; Kei-Ichi, F.; Hiroshi, K. *J. Antibiotics* **1968**, 21, 300-305.
- [9] Upadhya, K. G.; Badami, B. V.; Puranik, G. S. *Arch. Pharm.* **1980**, 313, 684-688.
- [10] Lamberth, C. *Heterocycles* **2007**, 71, 1467-1502.
- [11] Eicher, T.; Hauptmann, S.; Speicher, A. (Eds.) *The Chemistry of Heterocycles*, 2nd Ed., Wiley, New York, **2003**, p 179.


- [12] Adams, J. L.; Gallagher, T.; Osifo, I. K. PCT Int. Appl. WO9856377, **1998**; *Chem. Abstr.* **1999**, 130, 52415.
- [13] Fink, B. E.; Mortensen, D. S.; Stauffer, S. R.; Aron, Z. D.; Katzenellenbogen, J. A. *Chem. Biol.* **1999**, 6, 205-219.
- [14] Tsuji, K.; Nakamura, K.; Konishi, N.; Tojo, T.; Ochi, T.; Senoh, H.; Matsuo, M. *Chem. Pharm. Bull.* **1997**, 45, 987-995.
- [15] Kudo, N.; Furuta, S.; Tanigushi, M.; Endo, T.; Sato, K. *Chem. Pharm. Bull.* **1999**, 47, 857-868.
- [16] Yıldırım, M.; Dürüst, Y. *Tetrahedron* **2011**, 6, 3209-3215.
- [17] Dürüst, Y.; Yıldırım, M.; Fronczek, C. F.; Fronczek, F. R. *Monatsh. Chem.* **2012**, 143, 127-138.
- [18] Dürüst, Y.; Sağırılı, A.; Fronczek, F. R. *Mol. Divers.* **2011**, 15, 799-808.
- [19] Dürüst, Y.; Karakuş, H.; Kaiser, M.; Tasdemir, D. *Eur. J. Med. Chem.* **2012**, 48, 296-304.
- [20] Nintinchandra, N.; Kalluraya, B.; Aamir, S.; Shabaraya, A. R. *Eur. J. Med. Chem.* **2012**, 54, 597-604.
- [21] Fang, Y.; Wu, C.; Larock, R. C.; Shi, F.; *J. Org. Chem.* **2001**, 21, 8840-8851.
- [22] Ağırbaş, H.; Sümengen, D.; Dürüst, Y.; Dürüst, N. *Synth. Commun.* **1992**, 22, 209-217.
- [23] Dürüst, Y.; Karakuş, H.; Yavuz, M. Z.; Gepdiremen, A. *ATurk. J. Chem.* **2014**, 38, 739-755.
- [24] Huang, Z.; Wang, R.; Sheng, S.; Zhou, R.; Cai, M. *React. Funct. Polym.* **2013**, 73, 224-227.

- [25] Girard, C.; Önen, E.; Aufort, M.; Beauviere, S.; Samson, E.; Herscovici, J. *Org. Lett.* **2006**, 8, 1689-1692.
- [26] Thoman, C. J.; Voaden, D. J.; Hunsberger, I. M. *J. Org. Chem.* **1964**, 29, 2044-2045.
- [27] Yeh, M. Y.; Tien, H. J. *J. Chin. Chem. Soc.* **1986**, 33, 83-89.
- [28] Yeh, M. Y.; Nonaka, T.; Goto, T.; Hsu, M. C.; Fuchigami, T.; Tien, H. J. *Bull. Chem. Soc. Jpn.* **1983**, 56, 3535-3536.
- [29] Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. *Adv. Drug. Deliv. Rev.* **2012**, 64, 4-17.
- [30] Lipinski, C. A.; Litterman, N. K.; Southan, C.; Williams, A. J.; Clark, A. M.; Ekins, S. *J. Med. Chem.* **2015**, 58, 2068-2076.
- [31] Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. *Adv. Drug. Deliv. Rev.* **1997**, 23, 3-25.

Table 1. Estimated Lipinski values for the **13,15,17**.


Entry	R(Sydnone N3-substitution)	cLogP	Solubility	MW	TPSA	Druglikeness	Drugscore
13a	C ₆ H ₄ -Me	-3.13	-4.39	472.0	157.2	0.64	0.54
13b	C ₆ H ₄ -OMe	-3.54	-4.06	488.0	166.4	2.1	0.62
13c	C ₆ H ₄ -Br	-2.75	-4.88	536.0	157.2	0.09	0.41
15a	C ₆ H ₄ -Me	-2.11	-4.28	467.0	162.3	-10.6	0.33
15b	C ₆ H ₄ -OMe	-2.52	-3.95	483.0	171.6	-9.09	0.34
17a	C ₆ H ₄ -Me	-1.43	-4.36	401.0	122.6	-2.54	0.39
17b	C ₆ H ₄ -OMe	-1.84	-4.03	417.0	131.8	-1.05	0.47
17c	C ₆ H ₄ -Br	-1.04	-4.85	465.0	122.6	-3.11	0.32
17d	CH ₃	-3.16	-3.04	325.0	122.6	-1.25	0.54

Scheme 1. Synthesis of *N*-aryl sydrones **5a-f**.




Accepted Manuscript

Scheme 2. Synthesis of sydnone-4-carboxamidoximes **9a-d**.




Accepted Manuscript

Scheme 3. Synthesis of azido sydnone **11a-d**.




Accepted Manuscript

Scheme 4. Cycloaddition of azido sydnone **11a-c** with *N*-phenyl maleimide **12**.




Accepted Manuscript

Scheme 5. Cycloaddition of azido sydnones **11a,b** with phenyl vinyl sulfone **14**.




Accepted Manuscript

Figure 1. X-Ray ORTEP view of **10c**.




Accepted Manuscript

Figure 2. X-Ray ORTEP view of **13b**.



Accepted Manuscript

Figure 3. X-ray ORTEP view of **17b**.



Accepted Manuscript